Serum inter-alpha-trypsin inhibitor and matrix hyaluronan promote angiogenesis in fibrotic lung injury.

RATIONALE The etiology and pathogenesis of angiogenesis in idiopathic pulmonary fibrosis (IPF) is poorly understood. Inter-alpha-trypsin inhibitor (IaI) is a serum protein that can bind to hyaluronan (HA) and may contribute to the angiogenic response to tissue injury. OBJECTIVES To determine whether IaI promotes HA-mediated angiogenesis in tissue injury. METHODS An examination was undertaken of angiogenesis in IaI-sufficient and -deficient mice in the bleomycin model of pulmonary fibrosis and in angiogenesis assays in vivo and in vitro. IaI and HA in patients with IPF were examined. MEASUREMENTS AND MAIN RESULTS IaI significantly enhances the angiogenic response to short-fragment HA in vivo and in vitro. lal deficiency Ieads to decreased angiogenesis in the matrigel model, and decreases lung angiogenesis after bleomycin exposure in mice. IaI is found in fibroblastic foci in IPF, where it colocalizes with HA. The colocalization is particularly strong in vascular areas around fibroblastic foci. Serum levels of IaI and HA are significantly elevated in patients with IPF compared with control subjects. High serum IaI and HA levels are associated with decreased lung diffusing capacity, but not FVC. CONCLUSIONS Our findings indicate that serum IaI interacts with HA, and promotes angiogenesis in lung injury. IaI appears to contribute to the vascular response to lung injury and may lead to aberrant angiogenesis. Clinical trial registered with www.clinicaltrials.gov (NCT00016627).

[1]  D. Schwartz,et al.  Inter-α-Trypsin Inhibitor Attenuates Complement Activation and Complement-Induced Lung Injury1 , 2007, The Journal of Immunology.

[2]  W. Seeger,et al.  Safety and tolerability of bosentan in idiopathic pulmonary fibrosis: an open label study , 2007, European Respiratory Journal.

[3]  M. Mishima,et al.  Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. , 2007, Chest.

[4]  F. Martinez,et al.  Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. , 2006, American journal of respiratory and critical care medicine.

[5]  K. Brown,et al.  Fibroblast foci are not discrete sites of lung injury or repair: the fibroblast reticulum. , 2006, American journal of respiratory and critical care medicine.

[6]  R. Kannagi,et al.  SHAP Potentiates the CD44-mediated Leukocyte Adhesion to the Hyaluronan Substratum* , 2006, Journal of Biological Chemistry.

[7]  M. Selman,et al.  Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers. , 2006, Proceedings of the American Thoracic Society.

[8]  A. Tzouvelekis,et al.  Angiogenesis in Interstitial Lung Diseases: a pathogenetic hallmark or a bystander? , 2006, Respiratory research.

[9]  S. Nathan,et al.  Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. , 2006, Chest.

[10]  Baolin Zhang,et al.  Fibroblast Growth Factor-2 Is a Downstream Mediator of Phosphatidylinositol 3-Kinase-Akt Signaling in 14,15-Epoxyeicosatrienoic Acid-induced Angiogenesis* , 2006, Journal of Biological Chemistry.

[11]  H Page McAdams,et al.  Clinical and pathologic features of familial interstitial pneumonia. , 2005, American journal of respiratory and critical care medicine.

[12]  V. Hascall,et al.  Inter-α-trypsin Inhibitor, a Covalent Protein-Glycosaminoglycan-Protein Complex* , 2004, Journal of Biological Chemistry.

[13]  Ping Wang,et al.  Delayed administration of human inter-&agr; inhibitor proteins reduces mortality in sepsis , 2004, Critical care medicine.

[14]  M. Keane.  Angiogenesis and pulmonary fibrosis: feast or famine? , 2004, American journal of respiratory and critical care medicine.

[15]  K. Brown,et al.  Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. , 2004, American journal of respiratory and critical care medicine.

[16]  I. Noth,et al.  Effects of Interferon-γ 1b on Biomarker Expression in Patients with Idiopathic Pulmonary Fibrosis , 2004 .

[17]  P. Hasleton,et al.  Angiogenic cytokines in patients with idiopathic interstitial pneumonia , 2004, Thorax.

[18]  Takashi Suzuki,et al.  Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. , 2004, American journal of respiratory and critical care medicine.

[19]  R. Kerbel,et al.  Versican/PG‐M G3 domain promotes tumor growth and angiogenesis , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[20]  C. A. de la Motte,et al.  Endoplasmic Reticulum Stress Induces Hyaluronan Deposition and Leukocyte Adhesion* , 2003, Journal of Biological Chemistry.

[21]  R. Tennant,et al.  Enrichment for living murine keratinocytes from the hair follicle bulge with the cell surface marker CD34. , 2003, The Journal of investigative dermatology.

[22]  A. Nicholson,et al.  Interstitial vascularity in fibrosing alveolitis. , 2003, American journal of respiratory and critical care medicine.

[23]  E. Puré,et al.  Resolution of Lung Inflammation by CD44 , 2002, Science.

[24]  I. D. Johnston,et al.  American thoracic society/European respiratory society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias , 2002 .

[25]  M. Burdick,et al.  ENA-78 is an important angiogenic factor in idiopathic pulmonary fibrosis. , 2001, American journal of respiratory and critical care medicine.

[26]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[27]  K. Kimata,et al.  Defect in SHAP-Hyaluronan Complex Causes Severe Female Infertility , 2001, The Journal of Biological Chemistry.

[28]  N. Gibran,et al.  Vitronectin deficiency is associated with increased wound fibrinolysis and decreased microvascular angiogenesis in mice. , 2000, Surgery.

[29]  H. Kobayashi,et al.  Immunolocalization of hyaluronic acid and inter-alpha-trypsin inhibitor in mice , 1999, Cell and Tissue Research.

[30]  M. Burdick,et al.  Neutralization of the CXC chemokine, macrophage inflammatory protein-2, attenuates bleomycin-induced pulmonary fibrosis. , 1999, Journal of immunology.

[31]  R. Whyte,et al.  The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. , 1997, Journal of immunology.

[32]  J. Fraser,et al.  Hyaluronan: its nature, distribution, functions and turnover , 1997, Journal of internal medicine.

[33]  A. Freemont,et al.  Early‐response gene signalling is induced by angiogenic oligosaccharides of hyaluronan in endothelial cells. Inhibition by non‐angiogenic, high‐molecular‐weight hyaluronan , 1997, International journal of cancer.

[34]  J. Hogg,et al.  Proteoglycan deposition in pulmonary fibrosis. , 1996, American journal of respiratory and critical care medicine.

[35]  M. Burdick,et al.  Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macrophages. The role of HA size and CD44. , 1996, The Journal of clinical investigation.

[36]  W. Thurlbeck,et al.  Correlation of structure and function in idiopathic pulmonary fibrosis. , 1995, American journal of respiratory and critical care medicine.

[37]  D. Schwartz,et al.  Determinants of survival in idiopathic pulmonary fibrosis. , 1994, American journal of respiratory and critical care medicine.

[38]  R. Hynes,et al.  Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin. , 1993, Development.

[39]  R. Swerlick,et al.  HMEC-1: establishment of an immortalized human microvascular endothelial cell line. , 1992, The Journal of investigative dermatology.

[40]  R. Rodríguez-Roisín,et al.  Mechanisms of gas-exchange impairment in idiopathic pulmonary fibrosis. , 1991, The American review of respiratory disease.

[41]  R. Lundgren,et al.  Hyaluronan and type III procollagen peptide concentrations in bronchoalveolar lavage fluid in idiopathic pulmonary fibrosis. , 1989, Thorax.

[42]  I. Hampson,et al.  Angiogenesis induced by degradation products of hyaluronic acid. , 1985, Science.

[43]  J D Fulmer,et al.  Morphologic-physiologic correlates of the severity of fibrosis and degree of cellularity in idiopathic pulmonary fibrosis. , 1979, The Journal of clinical investigation.

[44]  M. Turner‐Warwick.  Precapillary Systemic-pulmonary Anastomoses , 1963, Thorax.

[45]  D. Schwartz,et al.  Inter-alpha-trypsin inhibitor attenuates complement activation and complement-induced lung injury. , 2007, Journal of immunology.

[46]  R. Savani,et al.  Hyaluronan-mediated angiogenesis in vascular disease: uncovering RHAMM and CD44 receptor signaling pathways. , 2007, Matrix biology : journal of the International Society for Matrix Biology.

[47]  V. Hascall,et al.  Inter-alpha-trypsin inhibitor, a covalent protein-glycosaminoglycan-protein complex. , 2004, The Journal of biological chemistry.

[48]  I. Noth,et al.  Effects of interferon-gamma 1b on biomarker expression in patients with idiopathic pulmonary fibrosis. , 2004, American journal of respiratory and critical care medicine.

[49]  A. Daugherty.  Pulmonary fibrosis: thinking outside of the lung , 2004 .

[50]  David A. Lynch,et al.  Idiopathic pulmonary fibrosis: Diagnosis and treatment: International Consensus Statement , 2000 .

[51]  Thomas D. Schmittgen,et al.  Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2 2 DD C T Method , 2022 .